These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 33854297)
21. Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies. Ansari AS; Amir Z; Williams GS Ophthalmol Ther; 2021 Mar; 10(1):193-200. PubMed ID: 33464558 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of fluocinolone acetonide sustained release implant (Retisert) dissociation during implant removal and exchange surgery. Nicholson BP; Singh RP; Sears JE; Lowder CY; Kaiser PK Am J Ophthalmol; 2012 Dec; 154(6):969-973.e1. PubMed ID: 22981365 [TBL] [Abstract][Full Text] [Related]
30. Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal". Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA Pharmacoeconomics; 2020 Jun; 38(6):649-651. PubMed ID: 32249398 [No Abstract] [Full Text] [Related]
31. Comment on 'Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal'. Jacob I; Butler K; Badora K; Gross V; Beiderbeck A; Morris S; McEwan P Pharmacoeconomics; 2020 Jun; 38(6):645-648. PubMed ID: 32249397 [No Abstract] [Full Text] [Related]
32. Fluocinolone acetonide intravitreal implant as a therapeutic option for severe Sjögren's syndrome-related keratopathy: a case report. Wasielica-Poslednik J; Pfeiffer N; Gericke A J Med Case Rep; 2019 Jan; 13(1):21. PubMed ID: 30674351 [TBL] [Abstract][Full Text] [Related]
33. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T; Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128 [TBL] [Abstract][Full Text] [Related]
35. Time to disease recurrence in noninfectious uveitis following long-acting injectable fluocinolone acetonide implant. Cai CX; Skalak C; Keenan RT; Grewal DS; Jaffe GJ Graefes Arch Clin Exp Ophthalmol; 2020 May; 258(5):1023-1030. PubMed ID: 32114654 [TBL] [Abstract][Full Text] [Related]
36. FLUOCINOLONE ACETONIDE IMPLANT FOR VOGT-KOYANAGI-HARADA DISEASE: Three-Year Outcomes of Efficacy and Safety. Heo JW; Cho BJ; Goldstein DA; Sepah YJ; Do DV; Nguyen QD Retina; 2016 Nov; 36(11):2124-2131. PubMed ID: 27333235 [TBL] [Abstract][Full Text] [Related]
37. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. Jaffe GJ Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800 [TBL] [Abstract][Full Text] [Related]
38. Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. Brumm MV; Nguyen QD Int J Nanomedicine; 2007; 2(1):55-64. PubMed ID: 17722513 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy. Bajwa A; Aziz K; Foster CS Retina; 2014 Nov; 34(11):2259-68. PubMed ID: 24999722 [TBL] [Abstract][Full Text] [Related]
40. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study. Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]